NCT00649324

Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg

Single-Dose Fasting In-Vivo Bioequivalence Study of Hydrochlorothiazide Tablets (50 mg; Mylan) to Hydrochlorothiazide Tablets (50 mg; Ivax) in Healthy Volunteers

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Mylan Pharmaceuticals Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objective of this study was to investigate the bioequivalence of Mylan's hydrochlorothiazide 50 mg tablets to Ivax's Hydrochlorothiazide 50 mg tablets following a single, oral 50 mg (1 x 50 mg) dose administered under fasting conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Hydrochlorothiazide Tablets 50 mg	50mg, single dose fasting
DRUG	Hydrochlorothiazide Tablets (50 mg	50mg, single dose fasting

Timeline

• Start date: 2005-10-01
• Primary completion: 2005-10-01
• Completion: 2005-10-01
• First posted: 2008-04-01
• Last updated: 2024-04-24

Locations

1 site across 1 country: United States